HELIOS

June 8, 2016June 8, 2016

ASCO 2016 – AbbVie’s Imbruvica Phase 3 Trials in Leukemia and Lymphoma Patients Show Long-Term Favorable Responses

News

AbbVie has just presented long-term data on Imbruvica (ibrutinib) effects in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), revealing its therapeutic potential in these diseases. The ... Read more

May 13, 2016May 13, 2016

FDA Expands Label for Imbruvica (ibrutinib), a Lymphoma Therapy, to Include Improved Survival and Safety

News

The U.S. Food and Drug Administration (FDA) recently approved an expansion to prescribing information for the kinase inhibitor Imbruvica (ibrutinib), based on improved survival, safety, and efficacy data from studies in people with chronic ... Read more